EP1945308A1 - Composition administree de maniere topique et destinee a etre utilisee comme un agent d'eclaircissement de la peau - Google Patents

Composition administree de maniere topique et destinee a etre utilisee comme un agent d'eclaircissement de la peau

Info

Publication number
EP1945308A1
EP1945308A1 EP06804797A EP06804797A EP1945308A1 EP 1945308 A1 EP1945308 A1 EP 1945308A1 EP 06804797 A EP06804797 A EP 06804797A EP 06804797 A EP06804797 A EP 06804797A EP 1945308 A1 EP1945308 A1 EP 1945308A1
Authority
EP
European Patent Office
Prior art keywords
skin
composition according
compounds
preparation
bleaching
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06804797A
Other languages
German (de)
English (en)
Inventor
Hugo Ziegler
Peter Wikstroem
Martin STÖCKLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of EP1945308A1 publication Critical patent/EP1945308A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur

Definitions

  • the present invention relates to topically applicable agents or compositions, in particular
  • Skin lightening agents or compositions for lightening the skin containing amidino or guanidinoalkyl disulfides, and the use of these compounds and of the compositions according to the invention for lightening the skin color, for depigmenting age spots and for compensating for irregularities in skin coloration.
  • Skin-lightening agents have an effect on melanin metabolism or melanin metabolism.
  • the usually brown to black-colored melanins are formed in the melanocytes of the skin, transferred to the keratinocytes and cause the color of the skin or hair.
  • the brown-black Eumelanine are in mammals mainly of hydroxy-substituted aromatic amino acids such as L-tyrosine and L-DOPA, the yellow to red pheomelanins additionally formed from sulfur-containing molecules such as cysteine (Cosmetics & Toiletries 1996, 111 (5), 43-51).
  • L-tyrosine the copper-containing key enzyme tyrosinase L-3,4-dihydroxyphenylalanine (L-DOPA) is formed, which in turn is oxidized by the tyrosinase via the red-brown colored dopaquinone to melanin.
  • L-DOPA copper-containing key enzyme tyrosinase L-3,4-dihydroxyphenylalanine
  • Undecylenoylphenylalanine, Hexapeptide-2 and Broussonetia Extract Powders need to be dosed relatively high to provide sufficient skin bleaching.
  • cystamine (2-aminoethyl) disulphide] as a non-toxic active substance is capable of effectively and reversibly depigmenting human melanoma cells as well as normal melanocytes (J. Invest. Dermatol., 2000, 21-27).
  • the effect of cystamine is based on the fact that in a first step, a reduction to cysteamine occurs, which then reacts with products of tyrosinase activity reactions and so the melanin synthesis, especially that of brown / black eumelanin in derogation.
  • the object of the present invention is to find inexpensive, easily prepared, highly effective, stable non-tyrosinase inhibiting agents which can be used in skin lightening agents.
  • the present invention relates to a topically applicable
  • Agent or a topically applicable composition, in particular for use as a skin whitening agent or composition for whitening the skin color and for bleaching age and pigmentation, characterized in that it comprises an effective amount of at least one compound of general formula (I) or Mixture of such compounds and / or an acid addition salt thereof contains
  • X is NH or a direct bond and n is 2, 3 or 4, preferably 2 or 3, mean.
  • the invention also relates to the use of the topically applicable composition according to the invention or of the topically applicable composition according to the invention, containing an effective amount of at least one compound of the general formula (I) or a mixture of such compounds and / or an acid addition salt of such compounds as a skin lightening agent or as a composition for lightening the skin color, bleaching of age and pigmentation marks and / or for balancing of irregularities in the skin coloration.
  • the invention also relates to the use of a compound of the above general formula (I) or a mixture of such compounds and / or an acid addition salt thereof, for the preparation of a topically applicable composition, or a topically applicable composition, in particular for use as a skin lightening agent or as Composition for lightening the color of the skin, for bleaching age and pigment spots and / or for compensating for irregularities in the skin color.
  • the compounds of formula (I) may form monovalent or divalent, uniform or mixed salts with acids, e.g. with inorganic acids such as hydrochloric, hydrobromic, sulfuric or phosphoric acid; or with suitable organic aliphatic saturated or unsaturated carboxylic acids, e.g. aliphatic mono- or dicarboxylic acids, such as formic acid, acetic acid,
  • aromatic carboxylic acids such as benzoic acid or salicylic acid
  • aromatic-aliphatic carboxylic acids such as mandelic acid or cinnamic acid
  • heteroaromatic carboxylic acids such as nicotinic acid
  • aliphatic or aromatic Sulfonic acids such as methanesulfonic acid or to
  • the guanidino compounds can be obtained on the one hand by amidation of the corresponding amino derivatives, as described, for example, in British Journal of Pharmacology 118, 1659-1668 (1996). On the other hand, they are accessible from aminoalkylisothiouronium salts by rearrangement and subsequent oxidation [Chem. Pharm. Bull. 14 (11), 1193-1201 (1966)].
  • the amidino derivatives can be prepared by reacting the cyanoalkyl disulfides, e.g. in WO03 / 072559 and according to the literature cited therein.
  • compositions or compositions according to the invention may contain the compound of the formula (I) or a mixture of these compounds and / or their salts in concentrations ranging between 0.005 and 50% by weight (w / w), preferably between 0.05 and 5% by weight (w / w), based on the weight of the compositions.
  • compositions or compositions according to the invention may be in the form of a solution, a dispersion, an emulsion or encapsulated in carriers, such as the macro-, micro- or nanocapsules, in liposomes or Chylomicrons, or included in macro, micro or nanoparticles, or in microspheres, or absorbed on powdered organic polymers, or mineral carriers such as talc, bentonite, and other mineral carriers.
  • carriers such as the macro-, micro- or nanocapsules, in liposomes or Chylomicrons, or included in macro, micro or nanoparticles, or in microspheres, or absorbed on powdered organic polymers, or mineral carriers such as talc, bentonite, and other mineral carriers.
  • topically applicable agents or compositions according to the invention can be used in any galenic form.
  • examples of such forms are: emulsions W / O and O / W, milk, lotions, ointments, gelling and viscous, stress active and emulsifying polymers, pomades, shampoos, soaps, gels, powders, sticks and sticks, sprays, body oils, face masks, patches ,
  • compositions or compositions according to the invention can comprise cosmetic auxiliaries and form compositions such as are customarily used in such preparations, for example sunscreens (for example organic or inorganic light filter substances, preferably micropigments), preservatives, bactericides, Fungicides, virucides, cooling agents, plant extracts such as Scutellaria extract, Saxifrage extract, peptides and their derivatives, enzyme inhibiting agents anti-inflammatory agents, astringent agents such as aluminum chlorohydrate and aluminum zirconium Tetra Chlorohydrex Glycine, the wound healing accelerating substances (eg chitin or chitosan and its derivatives ), film-forming substances (eg polyvinylpyrrolidones or chitosan or its derivatives), common antioxidants, vitamins (eg vitamin C and derivatives, tocopherols and derivatives, vitamin A and derivatives), 2-hydroxycarboxylic acids (eg citric acid, Glycolic acid, malic), bactericides, Fungicides,
  • Chelating agents eg ethylenediaminetetraacetic acid and derivatives.
  • the amounts of cosmetic or dermatological auxiliaries and perfumes to be used in each case can easily be determined by a person skilled in the art by simple trial and error, depending on the nature of the particular product.
  • the compositions according to the invention may also contain other skin lightening active ingredients.
  • the skin lightening agents of the present invention may also contain kojic acid, kojic acid derivatives, niacin / niacinamides, alpha-hydroxycarboxylic acids such as lactic acid, arbutin, arbutin derivatives, ascorbic acid, ascorbic acid derivatives such as sodium ascorbyl phosphate, magnesium ascorbyl phosphate and ascorbyl glucoside, hydroquinone, hydroquinone derivatives, glabridine in licorice, oleanoic acid, sulfur-containing molecules such as e.g. Glutathione or cysteine or other synthetic or natural skin whitening active ingredients, the latter also being in the form of an extract from plants, e.g. Bearberry extract, Mulberry extract, and rice extract can be used.
  • novel compositions can particularly preferably contain inorganic or organic sunscreens or UV blockers.
  • Inorganic sunscreen agents useful herein include the following metal oxides, such as titanium dioxide, zinc oxide, zirconium oxide, iron oxide, and mixtures thereof.
  • organic sunscreens examples include dicampher sulfonic acid (Mexoryl SX), dromitrizole trisiloxane (Mexoryl XL), 2-ethylhexyl p-methoxycinnamate (commercially available as PARSOL MCX), 4,4'-t-butylmethoxydibenzoylmethane (commercially available as PARSOL 1789), 2-hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, digalloyl trioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl 4- (bis (hydroxypropyl)) aminobenzoate, 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, 2-ethylhexyl salicylate, glyceryl p-aminobenzoate, 3, 3, ⁇ -trimethylcyclohexyl salicylate, methyl an
  • sunscreens such as those disclosed in US-A-4,937,370 issued to Sabatelli on June 26, 1990, and US-A-4,999,186 issued to Sabatelli & Spirnak on Jan. 12, 1990; March 1991, are disclosed.
  • the sunscreen agents disclosed therein have two distinct chromophore groups in a single molecule, which exhibit different ultraviolet radiation absorption spectra.
  • One of the chromophoric groups absorbs predominantly in the UV-B radiation range, and the other strongly absorbs in the UV-A radiation range.
  • Preferred compounds of this class of sunscreens are 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester of 2,4-dihydroxybenzophenone; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester with 4-hydroxy-dibenzoylmethane; 4-N, N- (2-ethylhexyl) methyl aminobenzoic acid esters of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone; 4-N, N- (2-ethylhexyl) -methylaminobenzoic acid ester of 4- (2-hydroxyethoxy) -dibenzoylmethane; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid
  • compositions of the invention also contain a dermatologically acceptable carrier.
  • dermatologically acceptable carrier means that the carrier is suitable for topical application to the horn tissue, has good aesthetic properties, is compatible with the active ingredients of the present invention and any other components and does not give rise to unfavorable safety or toxicity concerns.
  • the carrier can be in many different forms.
  • emulsion carriers including oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions are useful herein.
  • Water-in-silicone emulsions contain a continuous silicone phase and a dispersed aqueous phase.
  • compositions with a continuous aqueous phase and a hydrophobic, water-insoluble phase ("oil phase") dispersed therein.
  • oil phase hydrophobic, water-insoluble phase
  • suitable oil-in-water emulsion carriers are disclosed in US-A-5,073,371 to DJ Turner et al., Issued December 17, 1991, and US-A-5,073,372 to DJ Turner et al December 17, 1991.
  • a lotion was prepared by conventional methods according to the following recipe (in% by weight):
  • a cream was prepared by conventional methods according to the following recipe (in% by weight):
  • a sunscreen cream was prepared by conventional methods according to the following recipe (data in weight o ;.
  • Example 4 Determination of the reduction of the melanin content after the treatment of MelanoDerm tissues of the dark skin type with test substances • Material and Methods MelanoDerm Mel-300B Lot 6715 Kit G Long Life Maintenace Medium 1% SDS in 10 mM Tris, 0.05 mM EDTA pH 6.8 Proteinase K 5 mg / ml in 1% SDS in 10 mM Tris, 0.05 mM EDTA pH 6.8
  • Test substances compound 1 and cystamine as standard • Cultivation of the tissues and application of the test substances
  • the tissues treated according to the instructions of the manufacturer were transferred to 6 well plates containing 3 ml of medium per well , The tissues were placed on membrane inserts (Transwell Clear from Corning). 2 ml medium was added to the lower compartment, 1 ml to the upper compartment
  • test substances were applied topically as an aqueous solution. 10mM were applied per tissue. Every 48 hours, the medium and the test substance were renewed. For this purpose, the surface of the tissues was rinsed with 500 ⁇ l warm PBS and applied fresh test substance. After 8 days, the test substance was removed from two tissues per treatment type and for further cultivated for a further eight days with normal medium without test substance. The two other tissues per treatment were further incubated with test substance. The total duration of the experiment was 16 days.
  • the membranes with the pigmented epidermis were excised from the posts with a scalpel and transferred to Eppendorf tubes with screw cap. 200 ⁇ l of 1% SDS in 10 mM Tris, 0.05 mM EDTA pH 6.8 and 20 ⁇ l proteinase K were pipetted per tube. The Eppendorf tubes were incubated in a thermomixer at 45 0 C overnight. The next morning another 20 ⁇ l of proteinase K were pipetted into each tube and incubated for a further 6 hours. The lysate was basified by the addition of 25 ⁇ l of 500 mM NaHCO 3 and incubated for 30 min. incubated at 8O 0 C in a Thermomixer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pouvant être utilisée de manière topique, en particulier en tant qu'agent éclaircissant la peau. L'invention est caractérisée en ce que la composition comprend une quantité active d'au moins un composé de formule (I) ou un mélange desdits composés et/ou un sel d'addition acide. Dans cette formule, X représente NH ou une liaison directe et n représente 2, 3, 4, de préférence 2 ou 3. L'invention concerne également l'utilisation de la composition pour éclaircir la couleur de la peau, pour dépigmenter des tâches de vieillesse et pour équilibrer les irrégularités dans la coloration de la peau. L'invention concerne, de plus, des compositions actives de manière dermatologique, contenant au moins du disulfure de formule (I) et au moins un agent actif de soins dermatologiques supplémentaires.
EP06804797A 2005-10-12 2006-10-09 Composition administree de maniere topique et destinee a etre utilisee comme un agent d'eclaircissement de la peau Withdrawn EP1945308A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH16562005 2005-10-12
PCT/CH2006/000555 WO2007041884A1 (fr) 2005-10-12 2006-10-09 Composition administree de maniere topique et destinee a etre utilisee comme un agent d'eclaircissement de la peau

Publications (1)

Publication Number Publication Date
EP1945308A1 true EP1945308A1 (fr) 2008-07-23

Family

ID=35637088

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06804797A Withdrawn EP1945308A1 (fr) 2005-10-12 2006-10-09 Composition administree de maniere topique et destinee a etre utilisee comme un agent d'eclaircissement de la peau

Country Status (9)

Country Link
US (2) US20090169608A1 (fr)
EP (1) EP1945308A1 (fr)
JP (1) JP2009511509A (fr)
KR (1) KR20080063498A (fr)
CN (1) CN101282766A (fr)
BR (1) BRPI0617243A2 (fr)
CA (1) CA2625801A1 (fr)
TW (1) TW200744658A (fr)
WO (1) WO2007041884A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH700523A1 (de) * 2009-03-09 2010-09-15 Markus Luethy Neue Hautaufheller.
US9351922B2 (en) 2012-12-12 2016-05-31 Thomas Christopher Balshi Composition for correcting skin pigment conditions
CN109468825B (zh) * 2018-11-12 2021-06-15 武汉纺织大学 一种用于纺织品漂白的试剂组合物和纺织品漂白方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222100T1 (de) * 1993-10-21 2002-08-15 Searle & Co Amidino-derivate nützlich als no synthase-hemmer
JP3583158B2 (ja) * 1994-03-01 2004-10-27 有限会社野々川商事 化粧料
US5929063A (en) * 1995-03-24 1999-07-27 Children's Hospital Medical Center Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
US6596770B2 (en) * 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
JP2002087975A (ja) * 2000-09-13 2002-03-27 Pias Arise Kk 一酸化窒素産生抑制剤及び、その一酸化窒素産生抑制剤を配合した皮膚外用剤、化粧料、医薬部外品
ITMI20020756A1 (it) * 2002-04-09 2003-10-09 Sinclair Pharma S R L Composizioni farmaceutiche topiche per il trattamento delle dermatiti
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007041884A1 *

Also Published As

Publication number Publication date
CA2625801A1 (fr) 2007-04-19
US20090169608A1 (en) 2009-07-02
JP2009511509A (ja) 2009-03-19
US20120177710A1 (en) 2012-07-12
CN101282766A (zh) 2008-10-08
KR20080063498A (ko) 2008-07-04
TW200744658A (en) 2007-12-16
BRPI0617243A2 (pt) 2016-08-23
WO2007041884A1 (fr) 2007-04-19

Similar Documents

Publication Publication Date Title
KR101617478B1 (ko) 피부색 미백용 조성물
EP0945128B1 (fr) Utilisation de flavones, flavanones, ou de flavonoides pour la protection de l'acide ascorbique et/ou de liaisons de type ascorbyle contre l'oxydation
WO2008025755A1 (fr) utilisation d'hÉTÉrocycles contenant de l'azote dans les cosmÉtiques dermatologiques
WO2007012574A1 (fr) Preparations dermo-cosmetiques
DE102013204081A1 (de) Wirkstoffkombinationen aus Alkylamidothiazolen und einen oder mehreren kosmetisch oder dermatologisch unbedenklichen Konservierungsmitteln
WO2003059312A2 (fr) Preparations cosmetiques ou dermatologiques permettant d'empecher l'irritation cutanee par du peroxyde
DE60207026T2 (de) Verwendung von Pantetheinsulfonsäure und/oder ihren Salzen als Radikalfänger
EP1066821A1 (fr) Agent cosmétique topique contenant des benzaldoximes
DE19720339A1 (de) Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung
EP1214927A1 (fr) Utilisation de l' acide folique et/ou de ses dérivés pour la préparation de compositions topiques
DE10008907A1 (de) Topische kosmetische Mittel enthaltend benzokondensierte oder heterocyclisch kondensierte 2-Hydrazino-1,3-heteroazole
EP1945308A1 (fr) Composition administree de maniere topique et destinee a etre utilisee comme un agent d'eclaircissement de la peau
EP1881817A2 (fr) Utilisation de decomposeurs de peroxydes dans des produits cosmetiques et pharmaceutiques pour le soin de la peau
EP1166780A2 (fr) Utilisation de l'acide sulfinique physiologiquement acceptable comme agent antioxydant ou capteur de radicaux dans des préparations cosmétiques ou dermatologiques
EP3509566B1 (fr) Composés pour la reduction du contenu cellulaire de melanin
CN109195578B (zh) 硫代磷酸酯衍生物作为皮肤脱色剂的用途
EP1338269B1 (fr) Utilisation de créatinine et/ou des dérivés de créatinine pour éclaircir la peau et pour soulager les désordres de pigmentation
DE10002725A1 (de) Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung (skin whitening)
DE60118196T2 (de) Verwendung von einem liponsäuren-(r)-enantiomeren in kosmetika und dermatologie
JP2002114629A (ja) 化粧料
CA2338325C (fr) Nouvelles utilisations de l'ascorbyl-phosphoryl-cholesterol et compositions permettant de mettre en oeuvre ces nouvelles utilisations
JP2002121110A (ja) 化粧料
DE102008009799B4 (de) Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on gegen Hyperpigmentierung
CH700523A1 (de) Neue Hautaufheller.
CH703818A2 (de) Neue Hautaufheller.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080513

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20081008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121023